COVID-19 x cardiovascular system: clinical evolution, risk factors and myocardial injury mechanism
DOI:
https://doi.org/10.34119/bjhrv6n4-213Keywords:
SARS-CoV-2, cardiovascular system, infectious diseases, cardiovascular diseasesAbstract
SARS-CoV-2 has driven the COVID-19 epidemic around the world, making it one of the most significant medical challenges of the last century. This infectious agent infects host cells by binding to ACE2 receptors (an enzyme present in several tissues, such as the heart, lung and kidneys) and can lead to pneumonia, acute myocardial damage and chronic damage to the cardiovascular system. Pre-existing conditions such as diabetes, hypertension and obesity are related to greater severity and a significant increase in the fatality rate of COVID-19. The exacerbated production of inflammatory cytokines such as IL-6 and TNF-α leads to systemic inflammation, which can directly affect the cardiovascular system. Acute myocardial infarction (increased risk), myocarditis, arrhythmias, venous thromboembolism and takotsubo cardiomyopathy are some of the most prevalent complications of the cardiovascular system described in patients with COVID-19.
References
Croda JHR, Garcia LP. Resposta imediata da Vigilância em Saúde à epidemia da COVID-19. Epidemiologia e Serviços de Saúde [Internet]. 2020 Mar [cited 2021 Sep 23];29(1). Available from: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S2237-96222020000100100&lng=pt&nrm=iso&tlng=pt
Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020 Apr;181(2):271-280.e8.
Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet. 2020 Mar;395(10229):1054–62.
Ye Q, Wang B, Mao J. The pathogenesis and treatment of the `Cytokine Storm’ in COVID-19. Journal of Infection. 2020 Jun;80(6):607–13
Clerkin KJ, Fried JA, Raikhelkar J, Sayer G, Griffin JM, Masoumi A, et al. COVID-19 and Cardiovascular Disease. Circulation. 2020 May 19;141(20):1648–55.
Su S, Wong G, Shi W, Liu J, Lai ACK, Zhou J, et al. Epidemiology, Genetic Recombination, and Pathogenesis of Coronaviruses. Trends in Microbiology. 2016 Jun;24(6):490–502.
Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020 Apr 7;323(13):1239.
Patel VB, Zhong J-C, Grant MB, Oudit GY. Role of the ACE2/Angiotensin 1–7 Axis of the Renin–Angiotensin System in Heart Failure. Circ Res. 2016 Apr 15;118(8):1313–26.
Barbaro NR, Fontana V, Modolo R, De Faria AP, Sabbatini AR, Fonseca FH, et al. Increased arterial stiffness in resistant hypertension is associated with inflammatory biomarkers. Blood Pressure. 2015 Jan 2;24(1):7–13.
Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Stagliano N, et al. A Novel Angiotensin-Converting Enzyme–Related Carboxypeptidase (ACE2) Converts Angiotensin I to Angiotensin 1-9. Circulation Research [Internet]. 2000 Sep [cited 2021 Sep 23];87(5). Available from: https://www.ahajournals.org/doi/10.1161/01.RES.87.5.e1
Zou X, Chen K, Zou J, Han P, Hao J, Han Z. Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection. Front Med. 2020 Apr;14(2):185–92.
Magadum A, Kishore R. Cardiovascular Manifestations of COVID-19 Infection. Cells. 2020 Nov 19;9(11):2508.
Sugiura M, Hiraoka K, Ohkawa S, Ueda K, Matsuda T, Murakami M. A Clinicopathological Study on Cardiac Lesions in 64 Cases of Disseminated Intravascular Coagulation. Jpn Heart J. 1977;18(1):57–69.
Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. JAMA. 2020 May 26;323(20):2052.
Zuin M, Rigatelli G, Zuliani G, Rigatelli A, Mazza A, Roncon L. Arterial hypertension and risk of death in patients with COVID-19 infection: Systematic review and meta-analysis. Journal of Infection. 2020 Jul;81(1):e84–6.
Zheng Z, Peng F, Xu B, Zhao J, Liu H, Peng J, et al. Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis. Journal of Infection. 2020 Aug;81(2):e16–25.
Yang G, Tan Z, Zhou L, Yang M, Peng L, Liu J, et al. Effects of Angiotensin II Receptor Blockers and ACE (Angiotensin-Converting Enzyme) Inhibitors on Virus Infection, Inflammatory Status, and Clinical Outcomes in Patients With COVID-19 and Hypertension: A Single-Center Retrospective Study. Hypertension. 2020 Jul;76(1):51–8.
Guo T, Fan Y, Chen M, Wu X, Zhang L, He T, et al. Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020 Jul 1;5(7):811.
Babuin L, Vasile VC, Rio Perez JA, Alegria JR, Chai H-S, Afessa B, et al. Elevated cardiac troponin is an independent risk factor for short- and long-term mortality in medical intensive care unit patients: Critical Care Medicine. 2008 Mar;36(3):759–65.
Oudit GY, Kassiri Z, Jiang C, Liu PP, Poutanen SM, Penninger JM, et al. SARS-coronavirus modulation of myocardial ACE2 expression and inflammation in patients with SARS. European Journal of Clinical Investigation. 2009 Jul;39(7):618–25.
Sharma A, Garcia G, Wang Y, Plummer JT, Morizono K, Arumugaswami V, et al. Human iPSC-Derived Cardiomyocytes Are Susceptible to SARS-CoV-2 Infection. Cell Reports Medicine. 2020 Jul;1(4):100052.
Zhong J, Basu R, Guo D, Chow FL, Byrns S, Schuster M, et al. Angiotensin-Converting Enzyme 2 Suppresses Pathological Hypertrophy, Myocardial Fibrosis, and Cardiac Dysfunction. Circulation. 2010 Aug 17;122(7):717–28.
Zhong J, Guo D, Chen CB, Wang W, Schuster M, Loibner H, et al. Prevention of Angiotensin II–Mediated Renal Oxidative Stress, Inflammation, and Fibrosis by Angiotensin-Converting Enzyme 2. Hypertension. 2011 Feb;57(2):314–22.
Lupi L, Adamo M, Inciardi RM, Metra M. ACE2 down-regulation may contribute to the increased thrombotic risk in COVID-19. European Heart Journal. 2020 Sep 1;41(33):3200–3200.
Zhao X, Nicholls JM, Chen Y-G. Severe Acute Respiratory Syndrome-associated Coronavirus Nucleocapsid Protein Interacts with Smad3 and Modulates Transforming Growth Factor-β Signaling. Journal of Biological Chemistry. 2008 Feb;283(6):3272–80.
Cooper LT. Myocarditis. N Engl J Med. 2009 Apr 9;360(15):1526–38.
Prabhu SD. Cytokine-Induced Modulation of Cardiac Function. Circulation Research. 2004 Dec 10;95(12):1140–53.
Levi M, van der Poll T, Büller HR. Bidirectional Relation Between Inflammation and Coagulation. Circulation. 2004 Jun 8;109(22):2698–704.
Chen C, Zhou Y, Wang DW. SARS-CoV-2: a potential novel etiology of fulminant myocarditis. Herz. 2020 May;45(3):230–2.
Chen L, Li X, Chen M, Feng Y, Xiong C. The ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARS-CoV-2. Cardiovascular Research. 2020 May 1;116(6):1097–100.
Shi S, Qin M, Shen B, Cai Y, Liu T, Yang F, et al. Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China. JAMA Cardiol. 2020 Jul 1;5(7):802.
Hua A, O’Gallagher K, Sado D, Byrne J. Life-threatening cardiac tamponade complicating myo-pericarditis in COVID-19. European Heart Journal. 2020 Jun 7;41(22):2130–2130.
Inciardi RM, Lupi L, Zaccone G, Italia L, Raffo M, Tomasoni D, et al. Cardiac Involvement in a Patient With Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020 Jul 1;5(7):819.
Colombo CSS de S, Leitão MB, Avanza AC, Borges SF, Silveira AD da, Braga F, et al. Posicionamento sobre Avaliação Pré-participação Cardiológica após a Covid-19: Orientações para Retorno à Prática de Exercícios Físicos e Esportes – 2020. Arquivos Brasileiros de Cardiologia [Internet]. 2021 May 26 [cited 2021 Sep 23]; Available from: https://abccardiol.org/article/posicionamento-sobre-avaliacao-pre-participacao-cardiologica-apos-a-covid-19-orientacoes-para-retorno-a-pratica-de-exercicios-fisicos-e-esportes-2020/
Thygesen K, Alpert JS, Jaffe AS, Chairman BR, Bax JJ, Morrow DA, et al. Executive group on behalf of the Joint European Society of Cardiology (ESC)/American College of Cardiology (ACC)/American Heart Association (AHA)/World Heart Federation (WHF) Task Force for the Universal Definition of Myocardial Infarction. Fourth Univers Défin Myocard Infarct Glob Heart 2018;13:305–38.
Klok FA, Kruip MJHA, van der Meer NJM, Arbous MS, Gommers DAMPJ, Kant KM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thrombosis Research. 2020 Jul;191:145–7.
Wenzhong liu, hualan L. COVID-19:Attacks the 1-Beta Chain of Hemoglobin and Captures the Porphyrin to Inhibit Human Heme Metabolism [Internet]. 2020 Apr [cited 2021 Sep 23]. Available from: https://chemrxiv.org/articles/COVID-19_Disease_ORF8_and_Surface_Glycoprotein_Inhibit_Heme_Metabolism_by_Binding_to_Porphyrin/11938173/8
Shah RM, Shah M, Shah S, Li A, Jauhar S. Takotsubo Syndrome and COVID-19: Associations and Implications. Current Problems in Cardiology. 2021 Mar;46(3):100763.
Siripanthong B, Nazarian S, Muser D, Deo R, Santangeli P, Khanji MY, et al. Recognizing COVID-19–related myocarditis: The possible pathophysiology and proposed guideline for diagnosis and management. Heart Rhythm. 2020 Sep;17(9):1463–71.
Bikdeli B, Madhavan MV, Jimenez D, Chuich T, Dreyfus I, Driggin E, et al. COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up. Journal of the American College of Cardiology. 2020 Jun;75(23):2950–73.
Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020 May;18(5):1094–9
Lakkireddy DR, Chung MK, Gopinathannair R, Patton KK, Gluckman TJ, Turagam M, et al. Guidance for Cardiac Electrophysiology During the COVID-19 Pandemic from the Heart Rhythm Society COVID-19 Task Force; Electrophysiology Section of the American College of Cardiology; and the Electrocardiography and Arrhythmias Committee of the Council on Clinical Cardiology, American Heart Association. Circulation [Internet]. 2020 May 26 [cited 2021 Sep 23];141(21). Available from: https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.120.047063
Wu C-I, Postema PG, Arbelo E, Behr ER, Bezzina CR, Napolitano C, et al. SARS-CoV-2, COVID-19, and inherited arrhythmia syndromes. Heart Rhythm. 2020 Sep;17(9):1456–62.
Downloads
Published
Versions
- 08/23/2023 (2)
- 08/07/2023 (1)
